Feng Xu

US Patent:

6495713, Dec 17, 2002

Filed:

Jan 17, 2002

Appl. No.:

10/052088

Inventors:

Cheng Yi Chen - Plainsboro NJ
Weirong Chen - Iselin NJ
Paul OShea - Westmount, CA
Lushi Tan - Edison NJ
Richard Tillyer - Cranford NJ
Feng Xu - Staten Island NY
Philippe Dagneau - Verdun, CA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07C 6966

US Classification:

560179, 560187, 560188, 560198, 560201, 568 31, 568 32

Abstract:

This invention encompasses a process for making a compound of Formula A These compounds are intermediates useful in the preparation of certain non-steroidal anti-inflammnatory agents.

US Patent:

6569461, May 27, 2003

Filed:

Apr 26, 2000

Appl. No.:

09/558800

Inventors:

Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 900

US Classification:

424497, 424400, 424464, 424465, 424482, 424490

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

7034167, Apr 25, 2006

Filed:

Dec 5, 2003

Appl. No.:

10/729105

Inventors:

Kimberly A. Savary - Philadelphia PA, US
Zhiguo J. Song - Edison NJ, US
J. Michael Williams - Hillsborough NJ, US
Feng Xu - Staten Island NY, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 307/12

US Classification:

549478

Abstract:

A novel process is provided for the preparation of ribofuranose sugar derivatives which are useful in the synthesis of branched-chain ribonucleoside inhibitors of HCV polymerase for the treatment of HCV infection. Also provided are useful intermediates obtained from the instant process.

US Patent:

8022084, Sep 20, 2011

Filed:

Jan 26, 2006

Appl. No.:

11/813796

Inventors:

Daniel J. Kumke - Rahway NJ, US
Jerry A. Murry - Rahway NJ, US
Bryon L. Simmons - Rahway NJ, US
Feng Xu - Rahway NJ, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4355
C07D 498/04

US Classification:

514302, 546116

Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

US Patent:

20030176501, Sep 18, 2003

Filed:

Nov 13, 2002

Appl. No.:

10/293153

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US

International Classification:

C07C069/34
A61K031/225

US Classification:

514/548000, 560/146000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

US Patent:

20030211151, Nov 13, 2003

Filed:

Apr 29, 2003

Appl. No.:

10/425154

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Jose Vega - Trappe PA, US
Mandana Asgharnejad - Ambler PA, US

Assignee:

Merck & Co., Inc.

International Classification:

A61K031/225
A61K009/22
A61K009/16
A61K009/50

US Classification:

424/468000, 514/548000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

20050119343, Jun 2, 2005

Filed:

Nov 5, 2004

Appl. No.:

10/981866

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US

International Classification:

A61K031/225
C07C069/66

US Classification:

514548000, 560180000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

US Patent:

20100204486, Aug 12, 2010

Filed:

Apr 27, 2007

Appl. No.:

12/226801

Inventors:

Edward G. Corley - Freehold NJ, US
Jerry A. Murry - Rahway NJ, US
Bryon Simmons - Princeton NJ, US
Feng Xu - Staten Island NY, US

Assignee:

MERCK & CO., INC. - Rahway NJ

International Classification:

C07D 209/52
C07C 255/36
C07C 211/37
C07C 211/35

US Classification:

548452, 558410, 564307

Abstract:

The present invention is concerned with novel processes for the preparation of (+)-1-aryl-3-azabicyclo[3,10]hexanes or a pharmaceutically acceptable salt thereof, and (−)-1-aryl-3-azabicyclo[3,10]hexanes or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., pain, depression, anxiety disorders, eating disorders and urinary incontinence.